Tag: episode_1342

CONSIDER SOME HIGH ACTIVE SHARE FUNDS WITH LOW TURNOVER

April 7, 2017

CONSIDER SOME HIGH ACTIVE SHARE FUNDS WITH LOW TURNOVER

  • Most investors moving into passive index funds
  • Contrarian move would be to own a few actively managed funds
  • Add low turnover as a criteria

Watch the related WEALTHTRACK episode.

MILLER: WORLD CLASS BIBLIOPHILE

April 7, 2017

WORLD CLASS BIBLIOPHILE

Legendary investor Bill Miller is known for his stock picking ability and wide ranging intellectual interests, including his long time involvement at the Santa Fe Institute, a think tank specializing in complex systems, where he is now Chairman Emeritus. Always a voracious reader, in recent years he has turned into a serious bibliophile.

Watch the related WEALTHTRACK episode.

A RARE INTERVIEW: CONTRARIAN INVESTOR BILL MILLER DISCUSSES SOME OF HIS MOST CONTROVERSIAL HOLDINGS, INCLUDING VALEANT PHARMACEUTICALS

April 7, 2017

Legendary investor Bill Miller has always been an independent thinker and investor with a 100% “active share” in his funds, as different from any benchmark index as you can be. He is also now his own boss, having recently purchased 100% of his fund business from his long time employer Legg Mason and establishing his own investment advisory firm, Miller Value Partners. His two funds now bear his name and carry on his contrarian tradition of concentrated holdings in largely unloved stocks. His flagship Miller Opportunity Trust was the number one U.S. stock fund for the five year period ended in 2016. In a rare interview Miller gives his rationale for some of his most controversial holdings, including Valeant Pharmaceuticals.
Continue Reading »

Bill Miller – Independent Investor

April 7, 2017

This page is here for technical reasons. Please click here for the episode page.

PREMIUM: MILLER

April 6, 2017

INDEPENDENT INVESTOR

Legendary investor Bill Miller has always been an independent thinker and investor with a 100% “active share” in his funds, as different from any benchmark index as you can be. He is also now his own boss, having recently purchased 100% of his fund business from his long time employer Legg Mason and establishing his own investment advisory firm, Miller Value Partners. His two funds now bear his name and carry on his contrarian tradition of concentrated holdings in largely unloved stocks. His flagship Miller Opportunity Trust was the number one U.S. stock fund for the five year period ended in 2016. In a rare interview Miller gives his rationale for some of his most controversial holdings, including Valeant Pharmaceuticals.

Back to Top